Zimbabwe has turned down a substantial US health deal valued at $367m (272 million pounds) spanning five years due to the United States' insistence on confidential data.
This rejection became public following a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government spokesman has since explained that the US was demanding access to health data for scientific study and commercial gain while was not willing to share the benefits from future treatments.
"We will now turn to the challenging and unfortunate task of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had furnished more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for continued talks to find a agreement agreeable to all parties so the nation's vital HIV programme can continue.
Broader Context
This development comes after a comparable case in Kenya, where a high court halted a similar health funding agreement after concerns were filed about the safety of Kenyans' health data.
Since returning to office recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had managed aid for the US government, but Trump argued its spending was "wasteful" and his government was seeking direct bilateral agreements to enhance transparency and responsibility.
As per reports, Sixteen nations in Africa have to date agreed to similar health pacts, representing over $18.3bn in committed funds.
Details of the Rejected Agreement
The funds for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation would have delivered extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no corresponding guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"In essence, our country would supply the raw materials for scientific discovery with no assurance that the final treatments would be available to our people should a future health crisis arise."
Sovereignty and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral deals were disrupting frameworks already set up through the international organization.
The spokesperson cited its Pandemic Benefit-Sharing system created to deal with potential global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its samples, the resulting advantages – including medicines and cures – are shared equitably, not commercialised solely by those with the capability to develop them."
The government's concerns over the US deal "should not be misconstrued as opposition to America," he added.
"We encourage continued dialogue with our American counterparts on how future collaboration might be designed in a way that honours the sovereignty and dignity of each country."
Medical Community Reaction
A leading public health body said it recognised the government's concerns, but urged that negotiations should continue given that a large portion of the nation's HIV programmes were funded by foreign aid.
"In cases where specific concerns arise, such as those involving data governance or agreement terms, these can often be addressed via technical clarification and negotiated safeguards," the group said.
This impasse emphasises the continuing debate between receiving much-needed international aid and protecting national sovereignty in an increasingly data-driven world.